A006 DPI

Amphastar Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	A006 DPI
Also known as	Albuterol, Albuterol DPI
Sponsor	Amphastar Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006 (PHASE2)
Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation (PHASE2)
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients (PHASE2)
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation (PHASE2)
Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

A006 DPI CI brief — competitive landscape report
A006 DPI updates RSS · CI watch RSS
Amphastar Pharmaceuticals, Inc. portfolio CI